Blue Trust Inc. Sells 661 Shares of Bruker Co. (NASDAQ:BRKR)

Blue Trust Inc. trimmed its holdings in Bruker Co. (NASDAQ:BRKR) by 34.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,246 shares of the medical research company’s stock after selling 661 shares during the quarter. Blue Trust Inc.’s holdings in Bruker were worth $73,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Bruker by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company’s stock worth $779,000 after acquiring an additional 177 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock worth $53,000 after acquiring an additional 248 shares during the last quarter. US Bancorp DE lifted its holdings in shares of Bruker by 2.1% in the 3rd quarter. US Bancorp DE now owns 12,700 shares of the medical research company’s stock worth $877,000 after acquiring an additional 260 shares during the last quarter. Coldstream Capital Management Inc. lifted its holdings in shares of Bruker by 7.3% in the 3rd quarter. Coldstream Capital Management Inc. now owns 4,553 shares of the medical research company’s stock worth $312,000 after acquiring an additional 308 shares during the last quarter. Finally, National Bank of Canada FI lifted its holdings in shares of Bruker by 0.3% in the 3rd quarter. National Bank of Canada FI now owns 94,867 shares of the medical research company’s stock worth $6,551,000 after acquiring an additional 318 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on BRKR shares. The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a report on Thursday, December 5th. Bank of America upped their price target on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a report on Friday, December 13th. Wells Fargo & Company lowered their price target on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. TD Cowen lowered their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday, November 6th. Finally, Barclays lowered their price target on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $70.50.

Bruker Stock Down 4.0 %

Shares of Bruker stock opened at $50.82 on Monday. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. The company’s fifty day simple moving average is $56.73 and its two-hundred day simple moving average is $60.03. The company has a market cap of $7.70 billion, a P/E ratio of 66.87, a PEG ratio of 2.16 and a beta of 1.16. Bruker Co. has a 12-month low of $48.07 and a 12-month high of $94.86.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Research analysts anticipate that Bruker Co. will post 2.69 EPS for the current year.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.